摘要
目的评价盐酸替罗非班在急性ST段抬高心肌梗死(STEMI)患者冠状动脉介入治疗中的疗效和安全性。方法将310例接受冠状动脉急诊介入治疗的STEMI患者随机分为实验组和对照组各155例,均使用阿司匹林、氯吡格雷和肝素,实验组加用盐酸替罗非班,比较两组梗死相关血管开通后血流情况、ST段回落幅度、左室射血分数(LVEF)、住院期间主要不良心血管事件(MACE)发生率及出血、血小板减少等不良反应。结果与对照组比较,实验组校正TIMI帧数、无复流现象(TIMI 0～1级)降低(P均<0.05),术后90 min ST段回落幅度及术后1周LVEF值较高(P均<0.05)。两组MACE及不良反应发生率无统计学差异(P均>0.05)。结论急诊PCI前静脉应用盐酸替罗非班可以降低无复流发生率。
Objective To evaluate the efficacy and safety of tirofiban for coronary intervention in patients with acute myocardial infarction.Methods A total of 310 STEMI patients accepted emergency coronary intervention were randomly divided into 155 cases of tirofiban group and 155 patients of control group.Both groups were used aspirin,Plavix（clopidogrel） and common eparin,experimental group were used tirofeiban.Comparing effects of the tirofiban group and control group on blood flow after infarction,ST down range,postoperative left ventricular ejection fraction（LVEF）,adverse effects（bleeding,thrombocytopenia） and adverse cardiovascular events during hospital.Results Comparing with the control group,corrected TIMI frame count and no-reflow phenomenon reduced（P〈0.05）,ST down rang in 90 days and LVEF in 1 week were higher（P〈0.05）.The incidence of MACE between the two groups had no statistically significant.Conclusion The patients suffering acute myocardial infarction who were used tirofiban is safe and effective.
出处
《山东医药》
CAS
2012年第4期33-35,共3页
Shandong Medical Journal
